Affordable Access

Publisher Website

Monoclonal antibodies in myeloid diseases: Prognostic use in acute myeloid leukaemia

Authors
Journal
Leukemia Research
0145-2126
Publisher
Elsevier
Publication Date
Volume
15
Issue
8
Identifiers
DOI: 10.1016/0145-2126(91)90071-z
Keywords
  • Immunophenotyping
  • Acute Myeloid Leukaemia
  • Monoclonal Antibodies
  • Prognosis
Disciplines
  • Medicine

Abstract

Abstract Bone marrow cells from 109 patients (median age 60) with newly diagnosed acute myeloid leukaemia (AML) were prospectively immunophenotyped (IP) and the prognostic value of monoclonal antibody (MAB) reactivities was analysed to detect differences in complete remission rates and survival, not only between groups of MAB + and − bone marrow cells, but also in cases with or without prominent MAB reactivity as compared to normal BM reactivity of the respective MABs. This approach was based on the assumption that the qualitative expression of antigens is not an all or none phenomenon, but that different degrees of expression of antigens exist. Patients with significantly elevated CD13 (MY7+) cells in bone marrows (CD13 > reference value + one standard deviation) (S.D.) showed decreased probability of entering CR ( p < 0.05) and a significantly shorter survival ( p < 0.05). Superior CR rates ( p < 0.05) without difference in long-term survival were seen in patients with low CD33 (MY9) or low HLA-DR expression, while high CD14 (MY4) expression showed a trend towards an adverse factor ( p = 0.12). No other antibody reactivities showed differences in CR rates (CD3, CD20, CDw65 (VIM-2) and NAT-9). The more prominent bone marrow expression of CD33 antigen than CD13 (CD33/CD13 > 1) correlated to a better chance of entering CR ( p = 0.01) and to improved survival ( p = 0.002), while the expression of high numbers of VIM-2+ cells was a favourable prognostic factor regarding length of survival ( p = 0.002). The importance of a high CD33/CD13 ratio as a positive prognostic factor was evaluated using stratified analysis according to age or leucocyte counts at presentation. In both cases, CD33/CD13 was associated with longer survival (age: p = 0.05, leucocyte counts: p = 0.03). A Cox multiparameter analysis revealed that the CD33/CD13 ratio was a favourable prognostic factor ( p = 0.03) together with age ( p = 0.001) and leucocyte counts in peripheral blood ( p < 0.01). We conclude that establishing the immunologic phenotype can be of prognostic value in cases of AML, especially with regard to the relationship between the CD33 and CD13 antigens.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Immunophenotyping in acute leukaemia, myelodysplas...

on Danish medical bulletin February 1994

Prognostic factors in acute myeloid leukaemia.

on Best practice & research. Clin... March 2001

Prognostic factors in acute myeloid leukaemia

on Best Practice & Research Clini... Jan 01, 2001
More articles like this..